• Wasim Maziak.
• Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida; and Syrian Center for Tobacco Studies, Aleppo, Syria. Electronic address: wmaziak@fiu.edu.
• Am J Prev Med. 2014 Oct 1; 47 (4): 505507505-7.

AbstractThe recent popularity of electronic (e)-cigarettes and their rapid uptake by youth has ignited the debate about their role as a harm-reduction strategy. Harm reduction in the context of tobacco control contends that in societies that have achieved considerable success in curbing smoking, leaving the remaining hard-to-quit smokers with an abstinence-only option is unfair, especially when less-harmful choices are available. On one side of the debate are those who call for caution in endorsing such products until critical pieces of evidence about their safety and potential become available, whereas the other side argues that waiting until all questions about e-cigarettes are answered is dogma driven. In this piece, I try to discuss the unresolvable contention between harm-reduction goals of offering safer options to smokers, and those of e-cigarette makers of being commercially viable and profitable.Copyright © 2014 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…